Why AQST lags the market
Down 36% over five years while the S&P 500 rose 73%.
“The 41% decrease was primarily driven by the quarterly fluctuation of Suboxone product orders.”
AQST's Quality Score rose 4 points on Fri, Nov 13, to 1. More shares traded than usual (3 chart checks started).
Follow AQST's news. Pro members can get an alert when Aquestive Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 36% over five years while the S&P 500 rose 73%.
“The 41% decrease was primarily driven by the quarterly fluctuation of Suboxone product orders.”
| Holding it back | A $79M loss |
| Latest filing | 8-K, Nov 3 |
TodayNo company news in our sources; Biotech -0.6%, S&P 500 -0.4%.
AQST closed −11.9% that day on 2.0x normal volume.
Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.
After its last 4 reports it closed +1.5% on average, higher 1 of 4 times.
The company says its cash lasts into 2027 (8-K, May 13).
Director Richard J. Daly bought 28,025 shares on Nov 10. 15 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
AQST is #121 of 270 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 121 |
Expected to report Wed Mar 3, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $7.6M, 41% less than a year ago; a loss of $0.13 a share, from $0.14.
“The 41% decrease was primarily driven by the quarterly fluctuation of Suboxone product orders.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Manufacture and Supply Revenue | $6.7M | $11.9M | $11.5M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)
| Measure | Figure |
|---|---|
| Total revenue | $46.00 to $50.00 |
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | -5.7% | -2.1% | -9.3% |
| Aug 11, 2026 | -3.2% | -4.1% | -2.0% |
| May 13, 2026 | +15.0% | +14.5% | +1.0% |
Sales grew in three of the last seven years, to $44.5M in 2025. It lost money in each of the eight years.
RSI 47.8, MACD above signal, below both averages. Not scored.
One insider bought $99K across 2 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: AQST is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
“We compete with pharmaceutical and biotechnology companies that develop and commercialize therapeutics for the treatment of a broad range of disease areas and indications.”
AQST scores 1 today, which Breakaway calls Below Average. It is #121 of 270 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 36% over five years while the S&P 500 rose 73%. Shares: 13.5% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AQST scores 1 today, which Breakaway calls Below Average (0 to 5). That is #121 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AQST's 1.
One insider bought $99K across 2 filings in the last 6 months. No open-market sales on record. The newest is Richard J. Daly, Director, who bought $95K on Nov 10. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.